Phosphodiesterase 4 Inhibitor class drugs

4 results

  • daliresp

    (roflumilast)
    AstraZeneca Pharmaceuticals LP
    DALIRESP® is indicated for reducing the risk of COPD exacerbations in patients with severe COPD linked to chronic bronchitis and a history of exacerbations. It is not a bronchodilator and should not be used for acute bronchospasm relief. The initial dose is 250 mcg for the first four weeks only.
    Medication Details
    Drug Interactions

  • otezla

    (apremilast)
    Amgen Inc
    OTEZLA is indicated for treating adult patients with active psoriatic arthritis, adults and pediatric patients (ages 6+, ≥20 kg) with moderate to severe plaque psoriasis, and adults with oral ulcers associated with Behçet's Disease.
    Medication Details

  • roflumilast

    (Roflumilast)
    MAJOR PHARMACEUTICALS
    Roflumilast Tablets are indicated for reducing COPD exacerbation risk in patients with severe COPD and chronic bronchitis. It is not a bronchodilator and is not intended for acute bronchospasm relief. The starting dose is 250 mcg for the first four weeks and is not the therapeutic dose.
    Medication Details
    Drug Interactions